Kazia Therapeutics talks positive pre-clinical data for EVT801 | News Direct

Kazia Therapeutics talks positive pre-clinical data for EVT801

Kazia Therapeutics Ltd
Digital Asset Direct by Kazia Therapeutics Ltd
Download PDF Download multimedia

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | December 06, 2022 11:45 AM Eastern Standard Time

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner tells Proactive he is encouraged by the publication in a peer-reviewed cancer research journal of positive pre-clinical data for EVT801, the company’s clinical-stage drug candidate in a trial for multiple forms of cancer. He also updates on the status and progress with the company's lead drug Paxalisib.

 

Contact Details

 

Proactive Investors

 

Jonathan Jackson

 

+61 413 713 744

 

Jonathan@proactiveinvestors.com

DOWNLOAD

project media

Tags

Kazia Therapeutics LtdbiotechhealthAsxproactiveAustraliaproactiveInvestors
News Direct Logo
Follow us on Facebook Follow us on LinkedIn
Get the latest from News Direct
Contact Us Pricing
Why News Direct
About us Features News Hub
Resources
Terms of Use Privacy Policy
newsdirect.com © 2024 News Direct Corp. All rights reserved. News Direct is a registered trademark.